Capivasertib plus Docetaxel
Phase 3Small molecule
Capivasertib plus Docetaxel is one of 49 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Metastatic Prostate Cancer
#DrugCompanyPhaseTrials
1Casodex
IIstituto Clinico Humanitas
Approved
Revia
TevaApproved
Xtandi
AstellasPhase 3
Zytiga
Johnson & JohnsonPhase 3
Taxotere
AAvyxa
Phase 3
Zoladex
TTerSera Therapeutics LLC
Approved
Erleada
Johnson & JohnsonPhase 3
Nubeqa
BayerPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Jevtana
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Capivasertib plus Docetaxel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKarolinska Institutet